ANTIPODES PARTNERS Ltd Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

ANTIPODES PARTNERS Ltd boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 238,749 shares of the biopharmaceutical company’s stock after buying an additional 33,170 shares during the quarter. Alnylam Pharmaceuticals accounts for approximately 2.2% of ANTIPODES PARTNERS Ltd’s holdings, making the stock its 22nd biggest position. ANTIPODES PARTNERS Ltd owned approximately 0.19% of Alnylam Pharmaceuticals worth $59,432,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock worth $1,792,542,000 after buying an additional 50,366 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock worth $550,837,000 after buying an additional 201,784 shares during the last quarter. Capital International Investors grew its position in Alnylam Pharmaceuticals by 1.8% during the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after buying an additional 64,560 shares during the period. Capital Research Global Investors increased its holdings in Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after buying an additional 214,908 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $390,438,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $251.48 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $287.55. The stock has a market cap of $31.81 billion, a price-to-earnings ratio of -93.84 and a beta of 0.37. The stock’s 50 day moving average price is $257.28 and its 200-day moving average price is $190.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to analysts’ expectations of $447.22 million. The business’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.21) EPS. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Bank of America lifted their target price on Alnylam Pharmaceuticals from $295.00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday. Leerink Partners increased their target price on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a report on Tuesday, June 25th. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Raymond James upped their price target on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Finally, Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. Seven analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $279.14.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 32,450 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the transaction, the director now directly owns 136 shares of the company’s stock, valued at $30,013.84. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the transaction, the chief executive officer now directly owns 80,534 shares in the company, valued at approximately $18,602,548.66. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David E. I. Pyott sold 32,450 shares of the business’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The disclosure for this sale can be found here. Insiders sold a total of 103,148 shares of company stock valued at $25,658,824 in the last three months. Company insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.